Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vortioxetine Clear all
Completed Phase 4 Interventional Results available

Vortioxetine for Menopausal Depression

NCT02234362
View directory record Official record
Conditions
Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
Interventions
vortioxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01163266
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Anaheim, California • Cerritos, California • Costa Mesa, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 4 Interventional

A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder

NCT02395510
View directory record Official record
Conditions
Panic Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Siyan Clinical Corporation
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 4 Interventional Results available

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

NCT02371980
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

NCT02170220
View directory record Official record
Conditions
Severe Hepatic Impairment
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT00707980
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 76 Years
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

NCT01491035
View directory record Official record
Conditions
Depressive Disorder, Anxiety Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Wichita, Kansas • Cincinnatti, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 4 Interventional Results available

The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

NCT02749721
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
vortioxetine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 4 Interventional Results available

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

NCT02972632
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Costa Mesa, California • Culver City, California • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 18, 2026, 3:37 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 18, 2026, 3:37 AM EDT
Not listed Phase 4 Interventional

Adjunctive Vortioxetine in Schizophrenia

NCT02357797
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms
Interventions
Vortioxetine, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Lauderdale Lakes, Florida • Grand Rapids, Michigan • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00730691
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vortioxetine, Duloxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
66
States / cities
Anaheim, California • Beverly Hills, California • Fresno, California + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

NCT06604520
View directory record Official record
Conditions
Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD), Frontotemporal Dementia, Behavioral Variant, Frontotemporal Dementia
Interventions
Vortioxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Not listed Phase 4 Interventional

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

NCT02294305
View directory record Official record
Conditions
Social Anxiety Disorder, Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00731120
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

NCT00672958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Birmingham, Alabama • Cerritos, California • Encino, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available

Vortioxetine for Binge Eating Disorder

NCT02528409
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 2 Interventional

Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study

NCT07000734
View directory record Official record
Conditions
Aging, Cognitive Decline, Older Adults, Cardiovascular, Sedentary Behaviors, Immune Senescence, Motor Function
Interventions
Risk managment, Dasatinib, Quercetin (dietary supplement), Vortioxetine
Behavioral · Drug · Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 4 Interventional Results available

Vortioxetine for Posttraumatic Stress Disorder

NCT02637895
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Placebo, Vortioxetine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting Early Phase 1 Interventional

Implantable Microdevice In Primary Brain Tumors

NCT04135807
View directory record Official record
Conditions
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Microdevice
Combination Product
Lead sponsor
Oliver Jonas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Terminated Phase 3 Interventional Results available

Vortioxetine to Prevent Return of Symptoms in Children With Depression

NCT05014919
View directory record Official record
Conditions
Depression
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Atlanta, Georgia • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available

Investigating the Effect of Vortioxetine in Adult ADHD Patients

NCT02327013
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Beverly Hills, California • Garden Grove, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 18, 2026, 3:37 AM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 18 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 18, 2026, 3:37 AM EDT